ABBV-400 in patients with advanced EGFR WT non-squamous NSCLC: results from a Phase I study
Автор: VJOncology
Загружено: 2024-09-17
Просмотров: 189
Описание:
Mariana Brandão, MD, PhD, Jules Bordet Institute, Brussels, Belgium, discusses findings from a Phase I study (NCT05029882) of ABBV-400, an antibody-drug conjugate (ADC) targeting c-Met, which is often overexpressed in non-small cell lung cancer (NSCLC).The Phase I study evaluated its safety and efficacy in patients with EGFR wild-type NSCLC that had progressed after prior treatments. In 48 patients, ABBV-400 demonstrated a tolerable safety profile with common side effects including anemia, nausea, and neutropenia. The preliminary objective response rate (ORR) showed potential antitumor activity and warrants further study in NSCLC subtypes. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
